BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Oncoshot Enters Collaboration Agreement With Omico

Oncoshot has just entered into a collaboration agreement with Omico, the Australian Genomic Cancer Medicine Centre. The respective parties were represented...

July 20, 2022 | News

Urgent support needed following the pandemic's effect on cancer screening services

Dry July Foundation is urging Australians to dig even deeper this Dry July to help people affected by cancer. So many Australians could not access vital li...

July 15, 2022 | News

ZIRCON Phase III Kidney Cancer Imaging Study Completes Enrolment

TLX250-CDx, which has received "Breakthrough Designation" from the U.S. Food and Drug Administration (FDA)1, is being developed as an imaging agent for use...

July 11, 2022 | News

Australian developed VIRALEZE™ nasal spray relaunched by LloydsPharmacy in the UK

Extensive antiviral testing undertaken at the globally renowned Scripps Research Institute in the United States show that VIRALEZE&trad...

July 01, 2022 | News

Australia’s PrOSPeCT Project Is Sequencing Thousands of Cancer Patients

This March, Australia launched the Precision Oncology Screening Platform Enabling Clinical Trials (PrOSPeCT), which will sequence the genomes of more t...

June 23, 2022 | News

Telix and Invicro Advance AI Partnership

TelixAITM seeks to increase the efficiency and reproducibility of clinicians' imaging assessments using advanced analysis capabilities with an initial...

June 15, 2022 | News

Jubilant Radiopharma Joins Illuccix® Pharmacy Partner Network

The expansion of the distribution network facilitates broader patient access to Illuccix across the country, expanding availability into new regional marke...

June 14, 2022 | News

RAD adds brain tumor technology to portfolio

Sublicensing of promising imaging & therapeutic radiopharmaceutical from leading US university, Case Western Reserve University (CWRU),&nbs...

June 13, 2022 | News

Telix and RefleXion Expand Partnership for Prostate Cancer Treatment

BgRT is the first and only cancer treatment designed to integrate PET technology as part of external-beam radiotherapy delivery. It uses PET tracers a...

June 13, 2022 | News

US FDA Clears IND for Cynata's Phase 2 Clinical Trial of CYP-001 in GvHD

Key Highlights: US FDA has cleared Cynata's IND application for a Phase 2 clinical trial of CYP-001 in patients with aGvHD – a major mil...

May 27, 2022 | News

Medison Pharma strengthening its commercial offering into Australia and New Zealand

Medison Pharma ("Medison"), a global pharma company focused on providing access to highly innovative therapies to patients in international mark...

May 24, 2022 | News

Novotech Sponsors Pre-ASCO China Summit: Go/No Go Decisions Based on Early Phase Oncology Trials

The Summit will feature insights from leading Novotech experts tapping decades of oncology clinical experience in the APAC region. They include:- Dr. Raman...

May 12, 2022 | News

Inmagene Receives FDA's IND Clearance for OX40 Antagonist

IMG-007 is highly potent at blocking the binding of OX40 to OX40L, thereby reducing OX40L-dependent downstream signaling and cytokine release by T cells. I...

May 03, 2022 | News

Inmagene Receives FDA's IND Clearance for OX40 Antagonist

IMG-007 is highly potent at blocking the binding of OX40 to OX40L, thereby reducing OX40L-dependent downstream signaling and cytokine release by T cells. I...

May 02, 2022 | News

Stay Connected